Firms

Felicis

New York, New York · Los Angeles, California · San Francisco, California · Seattle, Washington · San Mateo, California · San Francisco Bay Area

felicis.com

signal.nfx.com

goldi.ai

Technology venture firm founded in 2006, predominantly Seed/Series A according to firm portfolio statistics, with later-stage participation. Fund X USD 900m raised in June 2025 is distinct from firm-reported USD 4.1bn AUM labeled 2026. Historical through-2014 fund/check claims are not current policy. Direct historical EEG investment InteraXon/Muse is distinct from mental-health services and computational drug discovery.

Founded: 2006
Type: Venture capital

Funds4

Felicis Fund X2025-06-102025-06-10$900M
Official raised fund amount/vintage; exact announcement day for historical timeline unverified. Focus Fund I distinct from Fund VIII; not combined fund/AUM.
Felicis Fund IX20232023$825M
Official raised fund amount/vintage; exact announcement day for historical timeline unverified. Focus Fund I distinct from Fund VIII; not combined fund/AUM.
Felicis Focus Fund I20212021$300M
Official raised fund amount/vintage; exact announcement day for historical timeline unverified. Focus Fund I distinct from Fund VIII; not combined fund/AUM.
Felicis Fund VIII20212021$600M
Official raised fund amount/vintage; exact announcement day for historical timeline unverified. Focus Fund I distinct from Fund VIII; not combined fund/AUM.

Team

Investments

team@apexlogos.ai16 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities. Funds and investment stages | Vehicle or metric | Amount and status | Date and evidence | | --- | --- | --- | | Fund X / FV X | **US$900m raised**; announcement describes completed fundraising, not a target | Official [Fund X announcement](https://www.felicis.com/blog/fund-x), June 10, 2025. Latest-known core fund found after checking the current official site and newer-fund searches through October 6, 2026. | | Fund IX / FV IX | US$825m core fund, historical raised vehicle | Official [About timeline](https://www.felicis.com/about) assigns it to 2023; page undated, accessed October 6, 2026. Exact original announcement date not established here. | | Fund VIII and Focus Fund I | US$600m core vehicle **plus separate US$300m Focus Fund I** | Same official timeline, 2021 vintage; these are distinct vehicles, not a US$900m Fund VIII. | | Firm AUM | **US$4.1bn**, firm-reported, distinct from Fund X | Same official About page labels this 2026. No underlying valuation methodology or audited statement checked. | The official About page says 94% of investments are Seed or Series A and 83% are led/co-led. These are firm-reported portfolio statistics; they support a strong early-stage emphasis without establishing an exclusive stage restriction. Actual verified rounds below include Series B, C and D, which show later-stage activity historically. Current portfolio labels also include later stages. No independently verified current check-size range was found; the old Signal $100k–$1m range should remain explicitly historical. The Fund X announcement supports broad technological ambition and strong interest in AI, rather than a neurotech-specific fund mandate. Sources: [About](https://www.felicis.com/about), undated/accessed 2026-10-06; [Fund X](https://www.felicis.com/blog/fund-x), 2025-06-10. Funds recorded in Adex after this review: | Fund | Disclosed amount | Announcement / filing date | | --- | --- | --- | | Felicis Focus Fund I | USD 300000000 | 2021 | | Felicis Fund VIII | USD 600000000 | 2021 | | Felicis Fund IX | USD 825000000 | 2023 | | Felicis Fund X | USD 900000000 | 2025-06-10 |
team@apexlogos.ai17 hours ago
Match research 2026-10-06 / Felicis / sha256:af8cd94e2013ea6fa6d06df75409a851c65dfb100fbca437294989044c9dd3d2 / part 2 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. - **Series B, $10 million, announced May 7, 2015.** The [InteraXon-issued Presswire release](https://presswire.com/release/interaxon-raises-10-million-series-b-led-omers-ventures/) names Felicis Ventures as a participating firm; OMERS led. It describes EEG sensors, research access and brain-signal feedback and quotes Felicis founder Aydin Senkut about Muse. Again, the release prints dollars without specifying USD/CAD; firm check undisclosed. This directly confirms the investment belongs to Felicis, rather than merely a personal connection to Senkut. This is historical neurotech evidence, not evidence of an announced current neurotech allocation or willingness to invest in every type of BCI. Device specifications and clinical/consumer efficacy should be assessed separately; sensor counts differ across vintages. Adjacent categories are kept separate. The official portfolio lists **Elevate** as a brain-training app and **Elemy** as mental/behavioral healthcare; these descriptions do not establish neural sensing or stimulation. Recursion's drug-discovery source mentions possible neuroinflammation partnerships, but it does not make Recursion a direct neural-interface investment. General AI chips are deep tech without becoming neurotech solely because neural networks are involved. Sources: [portfolio](https://www.felicis.com/portfolio), undated/accessed 2026-10-06; [Recursion release](https://www.recursion.com/news/series-d), 2020-09-09. ## Conflicts, gaps and concrete Adex review notes 1. **Replace or date the historical summary.** Adex and Signal's through-2014 capital/check statements conflict with current scale. Official Fund X $900m and firm AUM $4.1bn should be stored as different dated measures; no new current check range is supported. 2. **Early funds have differing values.** The official timeline lists 2006 $4m, 2012 $71m and 2014 $120m versus snapshot/Signal $4.5m/$70m/$96m. Timing, rounding or later closes may explain this, but that was not established. Preserve source-specific vintages rather than silently overwriting historical values. 3. **Correct the Recursion round stage after review.** Snapshot's duplicate `Recursion` participation cites the Series D source while its extra metadata calls the stage `series-a`. The official release unambiguously says Series D and dates it 2020-09-09. Related Recursion Pharmaceuticals/Recursion Pharma names may refer to the same company and need identity review before deduplication. 4. **Correct Exowatt amount semantics after review.** Snapshot has $50m attached to the April 22, 2025 $70m announcement. Official release gives $35m equity + $35m debt; do not encode $70m as purely equity or Felicis' check. A later $50m extension appears on the company's [news index](https://www.exowatt.com/news) dated November 13, 2025, but its investor attribution was not verified here and should not be merged with the April event. 5. **Keep InteraXon attribution and currency caveats.** Two historical company-origin sources confirm firm participation. Some third-party databases list different Series B dates/amounts: [Gaebler](https://www.gaebler.com/VC-Funding-ED473EBE-D478-4076-B6C2-A2DE4F49117E-InteraXon-04-27-2015) lists April 27, 2015 and $11,060,556 citing a regulatory filing, while the company announcement is May 7/$10m. This may be filing/announcement timing or currency, but no reconciliation was established. Retain both as attributed claims; prioritize the company announcement for announcement date. 6. **Portfolio stage labels are not complete investment histories.** For example, Exowatt is tagged Seed on the firm portfolio although its April 2025 firm announcement says Felicis led Series A. Do not use a portfolio label to replace a verified specific financing stage. 7. **Unresolved scope:** no exact current check range, audited AUM, complete fund legal-vehicle mapping, individual ownership/check amounts or exhaustive neurotech/deep-tech portfolio established. The original snapshot's many remaining investments were not all audited. Current partner roles and multi-city Signal locations were not independently revalidated. All linked sources were accessed on **2026-10-06**. Publication/announcement dates are stated alongside each claim; undated live pages are identified as such. This file contains research recommendations only, with no authorized Adex updates.
team@apexlogos.ai17 hours ago
Match research 2026-10-06 / Felicis / sha256:af8cd94e2013ea6fa6d06df75409a851c65dfb100fbca437294989044c9dd3d2 / part 1 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. # Felicis - Exact Adex ID: `Felicis` - Canonical Adex URL: https://adex.page/firms/Felicis - Research date: 2026-10-06 - Status: complete research for later review; no Adex or database changes made. Felicis (historically Felicis Ventures), founded in 2006, is an active venture firm with a predominantly Seed/Series A investment pattern and a broad technology mandate. The latest-known announced core fund found is **Fund X, US$900 million, raised in June 2025**. Verified investments include nuclear microreactors, thermal energy storage, inference chips, computational drug discovery and **InteraXon/Muse's EEG brain-sensing technology**, giving direct historical neurotech evidence. Investment attribution below is to the firm, not partners' prior employers. ## Starting evidence: Adex and NFX Signal The saved exact-ID record, `data/research/_sources/Felicis.adex.json`, was retrieved through read-only MCP Search on 2026-10-06 at 19:29:36 UTC. It describes early consumer internet investing, prospective healthcare/energy/education interests, historical $100,000–$1 million checks and about $200 million of committed capital through 2014. Its fund figures include $4.5 million in 2006, $41 million in 2010, $70 million in 2012 and $96 million in 2014. Investor-profile check minimum, maximum and sweet spot are null. These historical descriptions are unsuitable as a current fund-size or check-size statement. [NFX Signal's Felicis Ventures firm page](https://signal.nfx.com/firms/felicis-ventures) was **directly read** on 2026-10-06. It repeats essentially the same older description, check range and funds through August 2014, gives founded 2006, and lists multiple US locations and co-investors. Rendered content varied across opens; the accessible version displayed a team heading without usable team profiles. Signal is a discovery source with undated, visibly stale content, not independent confirmation of current assets, checks or mandate. Matching text suggests Adex and Signal should not count as two independent sources. Snapshot investment leads include Interaxon ($6m and $10m rounds), Radiant, Exowatt, Recursion, Planet, Tera AI, Crusoe, and many general software investments. The findings below independently verify selected substantive deep-tech examples rather than assuming every baseline participation is correct. ## Funds and investment stages | Vehicle or metric | Amount and status | Date and evidence | | --- | --- | --- | | Fund X / FV X | **US$900m raised**; announcement describes completed fundraising, not a target | Official [Fund X announcement](https://www.felicis.com/blog/fund-x), June 10, 2025. Latest-known core fund found after checking the current official site and newer-fund searches through October 6, 2026. | | Fund IX / FV IX | US$825m core fund, historical raised vehicle | Official [About timeline](https://www.felicis.com/about) assigns it to 2023; page undated, accessed October 6, 2026. Exact original announcement date not established here. | | Fund VIII and Focus Fund I | US$600m core vehicle **plus separate US$300m Focus Fund I** | Same official timeline, 2021 vintage; these are distinct vehicles, not a US$900m Fund VIII. | | Firm AUM | **US$4.1bn**, firm-reported, distinct from Fund X | Same official About page labels this 2026. No underlying valuation methodology or audited statement checked. | The official About page says 94% of investments are Seed or Series A and 83% are led/co-led. These are firm-reported portfolio statistics; they support a strong early-stage emphasis without establishing an exclusive stage restriction. Actual verified rounds below include Series B, C and D, which show later-stage activity historically. Current portfolio labels also include later stages. No independently verified current check-size range was found; the old Signal $100k–$1m range should remain explicitly historical. The Fund X announcement supports broad technological ambition and strong interest in AI, rather than a neurotech-specific fund mandate. Sources: [About](https://www.felicis.com/about), undated/accessed 2026-10-06; [Fund X](https://www.felicis.com/blog/fund-x), 2025-06-10. ## Verified previous deep-tech investments Amounts are **total company financing rounds**, not Felicis checks. Technical descriptions are company/firm claims; funding verification does not validate engineering performance or clinical effectiveness. | Company | Technology rationale | Verified Felicis attribution, round and date | Supporting source | | --- | --- | --- | --- | | **Radiant Industries / Radiant Nuclear** | Factory-built portable nuclear microreactors; advanced nuclear engineering and hardware commercialization | Named **new participant** in **US$100m Series C**, announced **November 14, 2024**. DCVC led; Felicis did not lead this round. | [Radiant official announcement](https://www.radiantnuclear.com/news/series-c-announcement), 2024-11-14. Source says total venture funding then reached $160m, which is a separate cumulative metric. | | **Exowatt** | Modular dispatchable solar power: capture solar heat, store it in a long-duration thermal battery and convert it to electricity | **Felicis led** financing announced **April 22, 2025**. **US$70m Series A package consists of US$35m equity and US$35m debt** from HSBC Innovation Banking and other lenders. Felicis' own amount undisclosed. | [Company-issued GlobeNewswire release](https://www.globenewswire.com/news-release/2025/04/22/3065427/0/en/Exowatt-Closes-70-Million-in-Series-A-Funding-to-Deploy-and-Scale-the-Exowatt-P3.html), 2025-04-22; independently consistent attribution in [Felicis investment article](https://www.felicis.com/blog/investing-in-exowatt), same date. | | **Fractile** | Dedicated AI inference hardware; semiconductor/compute technology rather than an ordinary AI application | Firm confirms investment in **Series B**, **May 13, 2026**. The Felicis article establishes attribution and stage; round size and Felicis check not separately verified in this research. | [Felicis official investment announcement](https://www.felicis.com/blog/series-b-fractile), 2026-05-13. | | **Recursion Pharmaceuticals / Recursion** | High-throughput wet-lab experimentation, cellular imaging and machine learning for drug discovery | Felicis Ventures named among existing institutional investors participating in **US$239m Series D**, **September 9, 2020**. Leaps by Bayer led. | [Recursion official financing announcement](https://www.recursion.com/news/series-d), 2020-09-09. | | **InteraXon / Muse** | Non-invasive EEG sensing and real-time brain-signal feedback; direct neurotechnology hardware and algorithms | Verified historical firm participation; see detailed neurotech evidence below | Company-issued release and company financing statement reproduced in conference material, below. | These examples substantiate exposure across physical sciences, chips, biology and neurotechnology. They are selected examples, not a complete portfolio audit. The [official portfolio](https://www.felicis.com/portfolio), undated/accessed 2026-10-06, offers additional leads such as Ginkgo Bioworks, Guardant Health, Zipline and Crusoe, but no additional round-specific attribution is asserted here without verification. ## Verified previous neurotech investments **InteraXon (Muse): direct neurotechnology, firm-attributed.** Its Muse wearable measures EEG brain activity and provides real-time feedback; this is stronger neurotech evidence than a general mental-health service or a cognitive-training app. - **Series A, $6 million, announced August 15, 2013.** A company financing statement reproduced in the [Quebec City Conference 2013 participants guide](https://qcconference.com/wp-content/themes/ltio-global-theme/uploads/2013/ppf/QCC2013-PPF-Participants-Guide.pdf) explicitly names Felicis Ventures alongside Horizons Ventures, OMERS Ventures, A-Grade Investments, ff Venture Capital and Bridge Builders Collaborative. The statement describes Muse's brain-sensing headband and a six-sensor design. This is company-origin text on a third-party conference host; the original company news page was not located. Publication year 2013; announcement date stated within document. Currency is printed as dollars without a denomination in that excerpt; **do not silently convert it to CAD or assert USD**.
team@apexlogos.ai23 days ago
MATCH

Feyza Haskaraman Felicis, partner	$12M$8M – $15M	San Francisco, California
Astasia Myers Felicis, general_partner	$10M$100K – $35M	San Francisco Bay Area
Daniel Bartus Felicis, partner	$7M$500K – $15M	New York, New York
James Detweiler Felicis, general_partner	$7M$500K – $15M	San Francisco, California
Victoria Treyger Felicis, general_partner	$7M$500K – $15M	San Francisco, California
Ryan Isono Felicis, partner	$5M$500K – $10M	San Francisco, California
Aydin Senkut Felicis, managing_partner	—$500K – $15M	San Francisco Bay Area
Niki Pezeshki Felicis, general_partner	—$500K – $15M	San Francisco Bay Area
Tobi Coker Felicis, partner	—$500K – $15M	San Francisco Bay Area
Alexis Abrams Felicis, partner	—$500K – $15M	San Francisco Bay Area · San Francisco, California
Katie Riester Felicis, partner	—$500K – $15M	San Francisco Bay Area · San Francisco, California
Laura Buhler Felicis, partner	—$500K – $15M	San Francisco Bay Area · San Francisco, California
Mischa Vaughn Felicis, partner	—$500K – $15M	San Francisco Bay Area · San Francisco, California
Jake Storm Felicis, general_partner	—$500K – $15M	San Francisco, California
Javier Soltero Felicis, venture_partner	—$500K – $15M	San Francisco, California
Sundeep Peechu Felicis, general_partner	—$500K – $15M	San Francisco, California
Viviana Faga Felicis, general_partner	—$500K – $15M	San Francisco, California
Dasha Maggio Felicis, partner	—$500K – $15M	San Francisco, California · San Francisco Bay Area
Kristin Beach Felicis, partner	—$10K – $50K	San Mateo, California
Nancy Wang Felicis, venture_partner	—$500K – $15M	Seattle, Washington
Alex Stamos Felicis, Venture Partner	—— – —
Angela Dunning Felicis, Finance Manager	—— – —
Ben Mathes Felicis, Head of AI	—— – —
Brett Granberg Felicis, Investor	—— – —
Clarissa Eshelman Felicis, Office Manager	—— – —
Colette Keane Felicis, Marketing	—— – —
David Phu Felicis, Controller	—— – —
Elara Voss Felicis, Chief Product Officer Vision	—— – —
Elisa Schreiber Felicis, Chief Marketing Officer	—— – —
Enrique Guzman-Alvarez Felicis, Finance Manager	—— – —
Graham Littlehale Felicis, Partner	—— – —
Hanh Ha Felicis, Senior Partner Operations Manager	—— – —
Harley Finkelstein Felicis, Venture Partner	—— – —
John Anderson Felicis, Venture Partner	—— – —
Katherine Martinez Felicis, Partner Operations Manager	—— – —
Laurel Bylin Felicis, Marketing & Events Manager	—— – —
Lauren Infante Felicis, Junior Partner Operations Manager	—— – —
Lea Wengroff Felicis, Fund & IR Operations Manager	—— – —
Martin Tobon Felicis, Portfolio Analytics Manager	—— – —
Mateo Aranda Felicis, Head of Engineering Scale	—— – —
Melissa Forcier Felicis, Partner Operations & Office Manager	—— – —
Michelle Delcambre Felicis, Managing Director and General Partner	—— – —
Nini Hamrick Felicis, Investor	—— – —
Olivia Liao Felicis, Controller	—— – —
Peter Deng Felicis, General Partner	—— – —
Raychel Bailon Felicis, VP of Finance	—— – —
Ryan Thompson Felicis, Partner, General Counsel	—— – —
Sarah Dreyfus Felicis, Head of People	—— – —
Sonia Arrison Felicis, Venture Partner	—— – —
Teresa Chan Felicis, Chief Financial Officer & Co-Chief Operating Officer	—— – —
Thijn Lamers Felicis, Venture Partner	—— – —
Tianen Liang Felicis, Tax Controller	—— – —
Tony Shi Felicis, Partner	—— – —
Tyler Wilson Felicis, Finance Manager	—— – —
Vanessa Paredes Felicis, Senior Partner Operations Manager	—— – —
Zoe Siegel Felicis, Director of Talent	—— – —

Funds4

Team

Co-investing

Investments